Jason A. Amello

Jason A. Amello is recorded as Chief Accounting Officer at TScan Therapeutics, Inc. (TCRX) since January 29, 2024 and Board Member at TScan Therapeutics, Inc. (TCRX) since January 1, 2024. The newest filing on record that lists Jason A. Amello as Board Member at TScan Therapeutics, Inc. (TCRX) is dated April 17, 2026. Jason A. Amello was last confirmed as CFO at Candel Therapeutics, Inc. (CADL) in a filing dated May 23, 2023. TScan Therapeutics, Inc. reported in an 8-K filed September 30, 2026 that Jason A. Amello was terminated as Chief Financial Officer. TScan Therapeutics, Inc. reported in an 8-K filed September 2, 2026 that Jason A. Amello was terminated as Chief Financial Officer, effective September 2, 2026. TScan Therapeutics, Inc. reported in an 8-K filed April 2, 2026 that Jason A. Amello was appointed principal accounting officer, effective April 10, 2026. Equibles holds 7 filed executive changes naming Jason A. Amello; each is listed under recent activity with its source filing. The proxy statement of TScan Therapeutics, Inc. reports total compensation of $1,275,995 for Jason A. Amello in fiscal 2025, including a base salary of $520,000. Disclosed compensation is on record for 3 fiscal years. TScan Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at TScan Therapeutics, Inc. includes Gavin MacBeath (CEO and CFO), Stephen Biggar (Chairman), Brian Silver (CFO) and 7 others.